NCT05492799
Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE
Enrolling by Invitation
PHASE4All AgesInterventionalTreatmentAllievex Corporation
~15 participants
Updated 2023-08-09 on ClinicalTrials.gov
What's tested:AX 250
At a glance
Recruiting sites
0 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary - neurocognition
Measured over baseline to 144 weeks of treatment
Conditions
Where it's being run
6 sites across 6 statesCalifornia1
Pennsylvania1
Colombia1
Germany1
Turkey (Türkiye)1
United Kingdom1
Study leadership
- Medical Director · STUDY_DIRECTOR · Allievex Corporation
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Primary - neurocognitionbaseline to 144 weeks of treatment
the rate of change in score from neurocognitive assessment using validated scale